Post by UCB

Today, we welcome some extraordinary colleagues to the UCB family. With the closing of our acquisition of Candid Therapeutics, a talented team of scientists and innovators is now part of UCB. Candid was built with purpose: to redefine what is possible in autoimmune disease through T-cell engagers. That ambition aligns with everything we believe in at UCB. The science of T-cell engagers is moving fast, and the opportunity to reshape treatment expectations for patients with serious, underserved conditions is real and within reach. The T-cell engager space is evolving quickly, and the best chapters are still ahead. We look forward to writing them together. Together, we now have: • A growing pipeline of investigational T-cell engager assets targeting pathogenic B-cell populations • Shared expertise across biology, clinical development and immunology • A combined team motivated by one goal: meaningful outcomes for patients who need new options #Immunology #TCellEngagers #WelcomeCandid #TeamUCB